Eli Lilly s Branchburg, New Jersey, plant that makes a COVID antibody treatment is the subject of a Justice Department investigation, which was launched after workers document falsification claims.
A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.
Read more about Eli Lilly memo says firm did not make false statements to FDA on Business Standard. (Reuters) - A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing
Marisa TaylorMike SpectorDan Levine
1/2
Eli Lilly logo is shown on one of the company s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
Read More
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (LLY.N) focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giantâs COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world s largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.